A

Arcellx Inc
NASDAQ:ACLX

Watchlist Manager
Arcellx Inc
NASDAQ:ACLX
Watchlist
Price: 90.84 USD 4.15% Market Closed
Market Cap: 4.9B USD
Have any thoughts about
Arcellx Inc?
Write Note

Intrinsic Value

ACLX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ACLX stock under the Base Case scenario is 43.51 USD. Compared to the current market price of 90.84 USD, Arcellx Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACLX Intrinsic Value
43.51 USD
Overvaluation 52%
Intrinsic Value
Price
A
Base Case Scenario

Valuation Backtest
Arcellx Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ACLX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ACLX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Arcellx Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Arcellx Inc

Provide an overview of the primary business activities
of Arcellx Inc.

What unique competitive advantages
does Arcellx Inc hold over its rivals?

What risks and challenges
does Arcellx Inc face in the near future?

Has there been any significant insider trading activity
in Arcellx Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arcellx Inc.

Provide P/S
for Arcellx Inc.

Provide P/E
for Arcellx Inc.

Provide P/OCF
for Arcellx Inc.

Provide P/FCFE
for Arcellx Inc.

Provide P/B
for Arcellx Inc.

Provide EV/S
for Arcellx Inc.

Provide EV/GP
for Arcellx Inc.

Provide EV/EBITDA
for Arcellx Inc.

Provide EV/EBIT
for Arcellx Inc.

Provide EV/OCF
for Arcellx Inc.

Provide EV/FCFF
for Arcellx Inc.

Provide EV/IC
for Arcellx Inc.

Show me price targets
for Arcellx Inc made by professional analysts.

What are the Revenue projections
for Arcellx Inc?

How accurate were the past Revenue estimates
for Arcellx Inc?

What are the Net Income projections
for Arcellx Inc?

How accurate were the past Net Income estimates
for Arcellx Inc?

What are the EPS projections
for Arcellx Inc?

How accurate were the past EPS estimates
for Arcellx Inc?

What are the EBIT projections
for Arcellx Inc?

How accurate were the past EBIT estimates
for Arcellx Inc?

Compare the revenue forecasts
for Arcellx Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arcellx Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arcellx Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arcellx Inc compared to its peers.

Compare the P/E ratios
of Arcellx Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Arcellx Inc with its peers.

Analyze the financial leverage
of Arcellx Inc compared to its main competitors.

Show all profitability ratios
for Arcellx Inc.

Provide ROE
for Arcellx Inc.

Provide ROA
for Arcellx Inc.

Provide ROIC
for Arcellx Inc.

Provide ROCE
for Arcellx Inc.

Provide Gross Margin
for Arcellx Inc.

Provide Operating Margin
for Arcellx Inc.

Provide Net Margin
for Arcellx Inc.

Provide FCF Margin
for Arcellx Inc.

Show all solvency ratios
for Arcellx Inc.

Provide D/E Ratio
for Arcellx Inc.

Provide D/A Ratio
for Arcellx Inc.

Provide Interest Coverage Ratio
for Arcellx Inc.

Provide Altman Z-Score Ratio
for Arcellx Inc.

Provide Quick Ratio
for Arcellx Inc.

Provide Current Ratio
for Arcellx Inc.

Provide Cash Ratio
for Arcellx Inc.

What is the historical Revenue growth
over the last 5 years for Arcellx Inc?

What is the historical Net Income growth
over the last 5 years for Arcellx Inc?

What is the current Free Cash Flow
of Arcellx Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Arcellx Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Arcellx Inc

Current Assets 587.3m
Cash & Short-Term Investments 574.3m
Other Current Assets 13m
Non-Current Assets 177.6m
Long-Term Investments 102.4m
PP&E 71.4m
Other Non-Current Assets 3.7m
Current Liabilities 137m
Accounts Payable 6m
Accrued Liabilities 50.3m
Other Current Liabilities 80.7m
Non-Current Liabilities 144.9m
Other Non-Current Liabilities 144.9m
Efficiency

Earnings Waterfall
Arcellx Inc

Revenue
155.8m USD
Operating Expenses
-225.2m USD
Operating Income
-69.4m USD
Other Expenses
29m USD
Net Income
-40.4m USD

Free Cash Flow Analysis
Arcellx Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ACLX Profitability Score
Profitability Due Diligence

Arcellx Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
37/100
Profitability
Score

Arcellx Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ACLX Solvency Score
Solvency Due Diligence

Arcellx Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
77/100
Solvency
Score

Arcellx Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACLX Price Targets Summary
Arcellx Inc

Wall Street analysts forecast ACLX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACLX is 114.05 USD with a low forecast of 73.73 USD and a high forecast of 140.7 USD.

Lowest
Price Target
73.73 USD
19% Downside
Average
Price Target
114.05 USD
26% Upside
Highest
Price Target
140.7 USD
55% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ACLX?

Click here to dive deeper.

Dividends

Arcellx Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ACLX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ACLX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ACLX News

Profile

Arcellx Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.9B USD

Dividend Yield

0%

Description

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 78 full-time employees. The company went IPO on 2022-02-04. The firm is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The firm is advancing its CART-ddBCMA product through its iMMagine Phase 2 pivotal trial in patients with relapsed or refractory (r/r) multiple myeloma (MM). The firm is also advancing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, its D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. The company is also exploring indications in solid tumors.

Contact

MARYLAND
Gaithersburg
25 West Watkins Mill Road, Suite A
+12407236641.0
www.arcellx.com

IPO

2022-02-04

Employees

78

Officers

Chairman of the Board, CEO & President
Mr. Rami Elghandour
Chief Financial Officer
Ms. Michelle Lim Gilson
Chief Medical Officer
Dr. Christopher R. Heery M.D.
Chief Technical Officer
Mr. Narinderjeet Singh M.S.
Chief Scientific Officer
Mr. David Tice Ph.D.
Chief Investor Relations & Communications Officer
Ms. Myesha Lacy
Show More
General Counsel & Chief Legal Officer
Ms. Maryam Abdul-Kareem J.D., M.S.
Chief People Officer
Ms. Kate Aiken
Chief Commercial Officer
Mr. Neeraj P. Teotia
Chief Business Officer
Ms. Aileen Fernandes
Show Less

See Also

Discover More
What is the Intrinsic Value of one ACLX stock?

The intrinsic value of one ACLX stock under the Base Case scenario is 43.51 USD.

Is ACLX stock undervalued or overvalued?

Compared to the current market price of 90.84 USD, Arcellx Inc is Overvalued by 52%.

Back to Top